UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis

Kidney international reports, 2020-04, Vol.5 (4), p.494-502

2020

Volltextzugriff (PDF)

A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation

Journal of opioid management, 2016-11, Vol.12 (6), p.405

2016

Volltextzugriff (PDF)

4499 MATCHING-ADJUSTED INDIRECT COMPARISON OF SPARSENTAN VS DELAYED-RELEASE FORMULATION BUDESONIDE FOR PROTEINURIA REDUCTION IN ADULTS WITH IGA NEPHROPATHY

Nephrology, dialysis, transplantation, 2023-06, Vol.38 (Supplement_1)

2023

Volltextzugriff (PDF)

367 PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison

Nephrology, dialysis, transplantation, 2024-05, Vol.39 (Supplement_1)

2024

Volltextzugriff (PDF)

368 Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd

Nephrology, dialysis, transplantation, 2024-05, Vol.39 (Supplement_1)

2024

Volltextzugriff (PDF)

Complete Remission of Proteinuria in Patients with Focal Segmental Glomerulosclerosis Treated with Sparsentan, a Dual Endothelin and Angiotensin Receptor Antagonist, in the DUET Trial: SU-OR38

Journal of the American Society of Nephrology, 2020-10, Vol.31 (10S), p.55-55

2020

Volltextzugriff (PDF)

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)

Kidney international reports, 2019-11, Vol.4 (11), p.1633-1637

2019

Volltextzugriff (PDF)

Sa1398 Treatment With Naloxegol Versus Placebo: Safety Assessment in Patients Aged ≥65 Years With Noncancer Pain and Opioid-Induced Constipation

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-314-S-314

2015

Volltextzugriff (PDF)

Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis

American journal of kidney diseases, 2021-09, Vol.78 (3), p.340-349.e1

2021

Volltextzugriff (PDF)

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

The New England journal of medicine, 2023-12, Vol.389 (26), p.2436-2445

2023

Volltextzugriff (PDF)

Proteinuria End Points and Associations with Renal Survival in FSGS: Analysis of the UK National RaDaR Idiopathic Nephrotic Syndrome Cohort: PO1530

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.481-481

2021

Volltextzugriff (PDF)

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

Kidney international reports, 2023-10, Vol.8 (10), p.2017-2028

2023

Volltextzugriff (PDF)

Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response

United European gastroenterology journal, 2015-10, Vol.3 (5), p.471-480

2015

Volltextzugriff (PDF)

W1805 Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in NaïVE Patients

Gastroenterology (New York, N.Y. 1943), 2009, Vol.136 (5), p.A-865-A-865

2009

Volltextzugriff (PDF)

Natural History of Focal Segmental Glomerulosclerosis (FSGS): The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort: PO1529

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.480-481

2021

Volltextzugriff (PDF)

Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid‐Induced Constipation

Pain practice, 2018-04, Vol.18 (4), p.505-514

2018

Volltextzugriff (PDF)

Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation

Journal of cardiovascular pharmacology and therapeutics, 2018-07, Vol.23 (4), p.309-317

2018

Volltextzugriff (PDF)

Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir

Hepatology (Baltimore, Md.), 2009-01, Vol.49 (1), p.72-79

2009

Volltextzugriff (PDF)

Prevalence of cerebrotendinous xanthomatosis among patients diagnosed with early-onset idiopathic bilateral cataracts: final analysis

Journal of AAPOS, 2023-08, Vol.27 (4), p.208-211

2023

Volltextzugriff (PDF)

An Open‐Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects

Clinical pharmacology in drug development, 2017-07, Vol.6 (4), p.420-427

2017

Volltextzugriff (PDF)

Parametric models for spatially correlated survival data for individuals with multiple cancers

Statistics in medicine, 2008-05, Vol.27 (12), p.2127-2144

2008

Volltextzugriff (PDF)

Musculoskeletal disorders of the neck and shoulder in dental hygienists and dental hygiene students

Journal of dental hygiene, 2007, Vol.81 (1), p.10

2007

Volltextzugriff (PDF)

Modelling spatially correlated survival data for individuals with multiple cancers

Statistical modelling, 2007-07, Vol.7 (2), p.191-213

2007

Volltextzugriff (PDF)

The effect of different warming methods on sensory nerve conduction velocity in shipyard workers occupationally exposed to hand–arm vibration

International archives of occupational and environmental health, 2008-08, Vol.81 (8), p.1045-1058

2008

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Humans
(11)
Female
(8)
Male
(8)
Middle Aged
(8)
Adult
(7)
Naloxegol
(5)
Aged
(4)
Biological And Medical Sciences
(4)
Medical Sciences
(4)
Opioid-Induced Constipation
(4)
Proteinuria
(4)
Urology & Nephrology
(4)
Young Adult
(4)
Public, Environmental & Occupational Health
(3)
Sensory Nerve Conduction Velocity
(3)
Vibration - Adverse Effects
(3)
Administration, Oral
(2)
Adolescent
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation

4499 MATCHING-ADJUSTED INDIRECT COMPARISON OF SPARSENTAN VS DELAYED-RELEASE FORMULATION BUDESONIDE FOR PROTEINURIA REDUCTION IN ADULTS WITH IGA NEPHROPATHY

367 PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison

368 Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd

Complete Remission of Proteinuria in Patients with Focal Segmental Glomerulosclerosis Treated with Sparsentan, a Dual Endothelin and Angiotensin Receptor Antagonist, in the DUET Trial: SU-OR38

Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)

Sa1398 Treatment With Naloxegol Versus Placebo: Safety Assessment in Patients Aged ≥65 Years With Noncancer Pain and Opioid-Induced Constipation

Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

Proteinuria End Points and Associations with Renal Survival in FSGS: Analysis of the UK National RaDaR Idiopathic Nephrotic Syndrome Cohort: PO1530

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response

W1805 Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in NaïVE Patients

Natural History of Focal Segmental Glomerulosclerosis (FSGS): The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort: PO1529

Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid‐Induced Constipation

Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation

Early hepatitis B virus DNA reduction in hepatitis B e antigen–positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir

Prevalence of cerebrotendinous xanthomatosis among patients diagnosed with early-onset idiopathic bilateral cataracts: final analysis

An Open‐Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects

Parametric models for spatially correlated survival data for individuals with multiple cancers

Musculoskeletal disorders of the neck and shoulder in dental hygienists and dental hygiene students

Modelling spatially correlated survival data for individuals with multiple cancers

The effect of different warming methods on sensory nerve conduction velocity in shipyard workers occupationally exposed to hand–arm vibration

Suchergebnisse filtern